Completed PHASE2 INTERVENTIONAL 1-arm NCT00937560

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

A Single-arm Phase II Clinical Study Investigating the Addition of Bevacizumab to Carboplatin and Weekly Paclitaxel as First-line Treatment in Patients With Epithelial Ovarian Cancer

Sponsor: Hoffmann-La Roche

Conditions Ovarian Cancer

Interventions Bevacizumab Carboplatin Paclitaxel

Updated 7 times since 2017 Last updated: Oct 5, 2017 Started: Jun 25, 2009 Primary completion: Jul 31, 2012 Completion: Jul 1, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ovarian Cancer and is currently completed. Hoffmann-La Roche leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Dec 2017 [monthly]

Completed PHASE2

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alkmaar, Netherlands , Amsterdam, Netherlands , Avignon, France , Barcelona, Spain , Bordeaux, France , Brive-la-Gaillarde, France , Campobasso, Italy , Clamart, France , Dijon, France , Enschede, Netherlands and 36 more locations